HUHS015 - CAS 1453097-13-6
Catalog number:
Not Intended for Therapeutic Use. For research use only.
HUHS015 is a potent PCA-1/ALKBH3 inhibitor both in vitro and in vivo. The bioavailability (BA) of HUHS015 was 7.2% in rats after oral administration. As expected, continuously administering HUHS015 significantly suppressed the growth of DU145 cells, which are human hormone-independent prostate cancer cells, in a mouse xenograft model without untoward effects.
Publictions citing BOC Sciences Products
  • >> More
white solid powder
HUHS015; HUHS 015; HUHS-015
1.Improving the bioavailability and anticancer effect of the PCA-1/ALKBH3 inhibitor HUHS015 using sodium salt.
Mabuchi M1, Shimizu T1, Ueda M1, Sasakawa Y2, Nakao S1, Ueda Y3, Kawamura A4, Tsujikawa K3, Tanaka A5. In Vivo. 2015 Jan-Feb;29(1):39-43.
Prostate cancer antigen (PCA)-1/AlkB homologue 3 (ALKBH3) has been identified as a clinically significant factor and siRNA of PCA-1 inhibits DU145 proliferation both in vitro and in vivo. HUHS015 ( 1: ), a previous reported PCA-1 small-molecule inhibitor, was also effective without any obvious side-effects or toxicity. The potency of HUHS015, however, is not satisfying. We thought the reason is poor solubility of HUHS015 because insoluble material remained at the injection site after subcutaneous administration. To improve this inhibitor's solubility, we prepared various salts of HUHS015 and examined their solubility, which resulted in the selection of HUHS015 sodium salt ( 2: ) for further studies in vivo. Next, we compared the pharmacokinetics of 1: and 2: via several administration routes. We observed significant improvements in the pharmacokinetic parameters. For example, subcutaneous administration of 2: increased the area under the curve (AUC)0-24 by 8-fold compared to 1 and increased the suppressive effect on the proliferation of DU145 cells in a xenograft model.
2.Design and synthesis of prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitors as anti-prostate cancer drugs.
Nakao S1, Mabuchi M2, Shimizu T1, Itoh Y1, Takeuchi Y1, Ueda M1, Mizuno H2, Shigi N3, Ohshio I3, Jinguji K3, Ueda Y3, Yamamoto M4, Furukawa T4, Aoki S5, Tsujikawa K3, Tanaka A6. Bioorg Med Chem Lett. 2014 Feb 15;24(4):1071-4. doi: 10.1016/j.bmcl.2014.01.008. Epub 2014 Jan 11.
A series of 1-aryl-3,4-substituted-1H-pyrazol-5-ol derivatives was synthesized and evaluated as prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitors to obtain a novel anti-prostate cancer drug. After modifying 1-(1H-benzimidazol-2-yl)-3,4-dimethyl-1H-pyrazol-5-ol (1), a hit compound found during random screening using a recombinant PCA-1/ALKBH3, 1-(1H-5-methylbenzimidazol-2-yl)-4-benzyl-3-methyl-1H-pyrazol-5-ol (35, HUHS015), was obtained as a potent PCA-1/ALKBH3 inhibitor both in vitro and in vivo. The bioavailability (BA) of 35 was 7.2% in rats after oral administration. As expected, continuously administering 35 significantly suppressed the growth of DU145 cells, which are human hormone-independent prostate cancer cells, in a mouse xenograft model without untoward effects.
3.Effect of loading rate on the apparent fracture toughness of acrylic bone cement.
Lewis G1. Biomed Mater Eng. 2002;12(2):149-55.
In this study, a determination is made of the effect of loading rate, v (0.1 mm min(-1) versus 1.0 mm min(-1) versus 10 mm min(-1)) on the value of the plane strain fracture toughness, K(Ic), of three commercial formulations of acrylic bone cement (Osteopal), CMW3, and Copal), that are characterized as "low-", "medium-", and "high-" viscosity brands, respectively). For all formulations, K(Ic) increases with increase in v. However, while this trend is statistically significant for CMW3 and Copal, this is not so for Osteopal. The CMW3 and Copal results are explained in terms of changes of the molecular relaxation transitions in the cement and the thermal state at the crack tip of the test specimen. Two implications of the findings are discussed. In the case of Osteopal, a recommendation for further study is made.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products

CAS 770691-21-9 Gadobutrol

(CAS: 770691-21-9)

Gadobutrol is a nonionic, paramagnetic contrast agent developed for tissue contrast enhancement in magnetic resonance imaging (MRI). It has a macrocyclic framew...

CAS 37350-58-6 Metoprolol

(CAS: 37350-58-6)

Metoprolol, is a selective β1 receptor blocker medication used to treat high blood pressure, chest pain due to poor blood flow to the heart, and a number of con...

CAS 2998-57-4 Estramustine

(CAS: 2998-57-4)

Estramustine, a derivative of estradiol, is an alkylating antineoplastic agent that is used in the treatment of prostate cancer throughout the world.

CAS 68252-28-8 (R)-Oxiracetam

(CAS: 68252-28-8)

(R)-Oxiracetam is the (R)-enantiomer of the nootropic drug oxiracetam, which is a nootropic drug of the racetam family and stimulant. It is safe even when high ...

CAS 1135237-88-5 Exherin trifluoroacetate

Exherin trifluoroacetate
(CAS: 1135237-88-5)

Exherin trifluoroacetate is a small, cyclic pentapeptide vascular-targeting agent with potential antineoplastic and antiangiogenic activities, which selectively...

(CAS: 865608-11-3)

CMPD101 is a selective GRK2/3 inhibitor with IC50 value is 54 nM for GRK3 and 32 nM for GRK2. It shows selectivity for GRK2/3 over GRK1/5. It can also reduce DA...

CAS 73-48-3 rac Bendroflumethiazide

rac Bendroflumethiazide
(CAS: 73-48-3)

Bendroflumethiazide is a thiazide diuretic as a Na++Cl- symport inhibitor. Bendroflumethiazide can be used in the treatment of mild heart failure although loop ...

CAS 145375-43-5 Mitiglinide

(CAS: 145375-43-5)

Mitiglinide is a succinic acid derivative with hypoglycemic activity. It belongs to the meglitinide class of blood glucose-lowering drugs. It is a drug for the ...

CAS 3055-99-0 Polidocanol

(CAS: 3055-99-0)

A nonionic surfactant.

CAS 856676-23-8 Choline Fenofibrate

Choline Fenofibrate
(CAS: 856676-23-8)

Choline Fenofibrate is the choline salt of fenofibric acid under clinical development as a combination therapy with rosuvastatin for the management of dyslipide...

CAS 6877-32-3 Corynoxine

(CAS: 6877-32-3)

Corynoxine is an enantiomer of Corynoxine B. It induces autophagy in different neuronal cell lines, including N2a and SHSY-5Y cells. By inducing autophagy, it p...

CP 81282
(CAS: 121584-61-0)

CP 81282 shows human renin and endothiapepsin inhibitory efficacy, but no detailed data has been published yet.

KHK-IN-1 hydrochloride
(CAS: 1303470-48-5)

The hydrochloride salt form of KHK-IN-1 which is a ketohexokinase inhibitor that could have probable effect against diabetes and obesity by acting on Asp-27B in...

(CAS: 1251537-11-7)

Navamepent is an inflammation mediator inhibitor and lipid modulator originated by Resolvyx Pharmaceuticals and licensed to Auven Therapeutics in 2011. Treatmen...

CAS 915365-57-0 Cot inhibitor-1

Cot inhibitor-1
(CAS: 915365-57-0)

Cot inhibitor-1 is a COT/Tpl2 inhibitor.

(CAS: 1137359-47-7)

BRD7552 is an inducer of transcription factor PDX1, which increases insulin expression.

CAS 633-65-8 Berberine HCl

Berberine HCl
(CAS: 633-65-8)

Berberine HCl is a quaternary ammonium salt from the group of isoquinoline alkaloids.

CAS 1208313-97-6 Ketone Ester

Ketone Ester
(CAS: 1208313-97-6)

a ketone ester given orally as R,S-1,3-butanediol acetoacetate diester (BD-AcAc(2)) would delay CNS-OT seizures in rats breathing hyperbaric oxygen (HBO(2)). Ad...

TAT peptide

TAT peptide, derived from the transactivator of transcription (TAT) of human immunodeficiency virus, is a cell penetrating peptide (GRKKRRQRRRPQ).

CAS 328232-95-7 MK 0557

MK 0557
(CAS: 328232-95-7)

MK-0557 is a highly selective, orally administered neuropeptide NPY5R antagonist, could limit weight regain after very-low-calorie diet (VLCD)-induced weight lo...

Chemical Structure

CAS 1453097-13-6 HUHS015

Quick Inquiry

Verification code

Featured Items